Main Article Content
Cushing’s disease, pituitary surgery, second - line therapies, cost - analysis
Cushing’s disease (CD) is a rare disorder caused by increased pituitary secretion of adrenocorticotropic hormone (ACTH) resulting in elevated production of cortisol. It is associated with multiple adverse cardiovascular, metabolic, musculoskeletal and mental consequences. Patients with CD require substantial health care resources both in terms of treatment s with a curative intent and control of disease-related comorbidities. In this study, a cost of illness analysis was conducted to estimate the direct cost of CD care in Canada.
This was a retrospective cohort study of 86 CD patients. Data collection included patient demographic and disease related information, existing comorbidities, treatments received and all clinical outcomes. In addition, healthcare resource utilization to manage CD was also collected. Once the mean cost per patient was determined, the overall disease prevalence was used to estimate the total direct cost of illness in Canada.
The sample included 86 CD patients, with a mean age of 43 years at diagnosis, 72 % were female. All received a first line intervention consisting of transsphenoidal pituitary surgery (78%), bilateral adrenalectomy ( 5% ), radiation therapy (5% ) or medical therapy ± radiation (13%). In addition, 18 and 14 patients subsequently received a second and third line intervention, respectively. The mean cost was $ 85,946 per patient over the first three lines of therapy. Combining this estimate with the reported disease prevalence (5.5 patients per 100,000 [95%CI: 4.2 to 6.8]), the total direct cost of CD i n Canada was estimated to be approximately $ 80.6 milli on (95%CI: $61.5 to $99.6 million ) over the first 3 lines of therapy.
CD is a debilitating condition that is associated with substantial health care costs. Strategies that provide clinical cure or long term disease control need to be identified to reduce patient morbidity and to save health care costs in patients who remain uncontrolled.
2. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012;167:311 - 26.
3. Arnaldi G, Mancini T, Tirabassi G, Trementino L, Boscaro M. Advanc es in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. J Endocrinol Invest 2012;35:434 - 48.
4. Bertagna X, Guignat L, Groussin L, Bertherat J. Cushing's disease. Best Pract Res Clin Endocrinol Metab 2009 Oct;23:607 - 23.
5. Clayto n RN. Mortality in Cushing's disease. Neuroendocrinology 2010;92 Suppl 1:71 - 6.
6. Feelders RA, Hofland LJ. Medical treatment of Cushing's disease. J Clin Endocrinol Metab 2013;98 :425 - 38.
7. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol 2011;7 :279 - 89.
8. Losa M, Picozzi P, Redaelli MG, Laurenzi A, Mortini P. Pituitary radiotherapy for Cushing's disease. Neuroendocrinology 2010;92 Suppl 1:107 - 10.
9. Swearingen B, Wu N, Chen SY, Pulgar S, Biller BM. Health care resource use and cos ts among patients with C ushing disease. Endocr Pract 2011;17:681 - 90.
10. Ontario Case Costing Initiative. http://www.occp.com/mainPage.htm . Accessed August 2013.
11. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769 - 75 .
12. Statistics Canada 2013. Available at http://www.statcan.gc.ca/start - debut - eng.html (access ed October, 2013).